Benitec Biopharma Ltd ADR (BNTC) Stock Price, Quote & News

Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene thera...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 780 0819

Website: benitec.com

Address:

3940 Trust Way, Hayward, United States

Iightning Nov. 19 at 10:04 AM

1ightning® Options Trade Alert (Actionable) | Buy $BNTC Dec 19 $15 Call | Enter: $1.60 Exit: $2.46 | Profit: 53.89% ROI | https://1ightning.com

0 · Reply

BillionerOfKing Nov. 13 at 3:20 AM

$BNTC Current Stock Price: $13.45 Contracts to trade: $15 BNTC Nov 21 2025 Call Entry: $1.57 Exit: $3.05 ROI: 94% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AlertsAndNews Nov. 11 at 3:43 AM

$BNTC interesting insider buy here from a director. Benitec Biopharma Inc.: Aaron Cowen (Director, 10% Owner) Buys 1,481,481 Shares @ Avg Price $13.50 – Form 4

1 · Reply

justiceforb_85 Nov. 6 at 6:37 PM

$BNTC adding on this dip. Hopefully this company can avoid further offerings...

2 · Reply

tymerz Nov. 6 at 2:50 PM

$TERN next up after $BNTC today. BNTC $100M offering, TERN ready to unleash $300M $SPY

0 · Reply

OnTargetCapital Nov. 6 at 2:26 PM

$BNTC They needed to grab some money to pay for EOY bonuses. LOL

0 · Reply

DARKP00L Nov. 6 at 2:12 PM

$BNTC 09:02 on Nov. 06 2025 Benitec Biopharma shares are trading lower after the company announced the pricing of its $100 million offering. #tradeideas

0 · Reply

OpenOutcrier Nov. 6 at 2:06 PM

$BNTC (-14.4% pre) Benitec Biopharma prices $100 million stock offering at $13.50 per share https://ooc.bz/l/83526

0 · Reply

DonCorleone77 Nov. 6 at 11:39 AM

$BNTC Benitec Biopharma $100M share Spot Secondary priced at $13.50

0 · Reply

AStrokeOfLuck Nov. 6 at 6:02 AM

$BNTC

0 · Reply

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Nov 6, 2025, 12:19 AM EST - 13 days ago

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

Nov 5, 2025, 4:43 PM EST - 13 days ago

Benitec Biopharma Inc. Announces Proposed Public Offering

Nov 3, 2025, 7:10 AM EST - 16 days ago

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Nov 2, 2025, 7:00 PM EST - 16 days ago

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Sep 22, 2025, 4:05 PM EDT - 2 months ago

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Apr 15, 2025, 11:51 PM EDT - 7 months ago

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer

Mar 25, 2025, 8:00 AM EDT - 8 months ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

Feb 14, 2025, 8:10 AM EST - 9 months ago

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

Nov 26, 2024, 7:00 AM EST - 1 year ago

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Nov 14, 2024, 4:30 PM EST - 1 year ago

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

Oct 17, 2024, 3:35 PM EDT - 1 year ago

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts

Oct 14, 2024, 6:00 AM EDT - 1 year ago

Benitec Biopharma Announces Updated Investor Webcast Information

Oct 12, 2024, 6:30 AM EDT - 1 year ago

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Sep 26, 2024, 4:30 PM EDT - 1 year ago

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study

May 13, 2024, 8:15 AM EDT - 1 year ago

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

Feb 13, 2024, 8:00 AM EST - 1 year ago

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

Nov 30, 2023, 7:00 AM EST - 2 years ago

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Nov 17, 2023, 8:00 AM EST - 2 years ago

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Aug 11, 2023, 1:00 PM EDT - 2 years ago

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

Aug 8, 2023, 10:30 PM EDT - 2 years ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

Jul 25, 2023, 1:00 PM EDT - 2 years ago

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

May 15, 2023, 8:00 AM EDT - 2 years ago

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 8, 2023, 8:05 AM EDT - 2 years ago

Benitec Biopharma to Present at the OPMD International Conference

Feb 13, 2023, 8:00 AM EST - 3 years ago

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

Jan 23, 2023, 9:48 AM EST - 3 years ago

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Nov 10, 2022, 8:00 AM EST - 3 years ago

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Sep 16, 2022, 8:42 AM EDT - 3 years ago

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Sep 12, 2022, 10:06 PM EDT - 3 years ago

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

Sep 2, 2022, 8:00 AM EDT - 3 years ago

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

May 16, 2022, 8:15 AM EDT - 3 years ago

Benitec Biopharma Releases Q3 2022 Financial Results

Feb 14, 2022, 8:00 AM EST - 4 years ago

Benitec Biopharma Discloses Q2 2022 Financial Results

Nov 15, 2021, 8:00 AM EST - 4 years ago

Benitec Biopharma Discloses Q1 2022 Financial Results

Sep 20, 2021, 8:00 AM EDT - 4 years ago

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

Sep 13, 2021, 3:58 PM EDT - 4 years ago

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

Sep 8, 2021, 8:10 AM EDT - 4 years ago

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

Sep 8, 2021, 8:05 AM EDT - 4 years ago

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

Sep 8, 2021, 8:00 AM EDT - 4 years ago

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022

Apr 27, 2021, 9:55 PM EDT - 4 years ago

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

Apr 27, 2021, 4:44 PM EDT - 4 years ago

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

Mar 23, 2021, 5:03 PM EDT - 5 years ago

Benitec BioPharma Shares Rally: Technical Levels To Watch

Mar 23, 2021, 11:28 AM EDT - 5 years ago

Why DLPN Stock And BNTC Stock Are Popping Off Today

DLPN

Iightning Nov. 19 at 10:04 AM

1ightning® Options Trade Alert (Actionable) | Buy $BNTC Dec 19 $15 Call | Enter: $1.60 Exit: $2.46 | Profit: 53.89% ROI | https://1ightning.com

0 · Reply

BillionerOfKing Nov. 13 at 3:20 AM

0 · Reply

AlertsAndNews Nov. 11 at 3:43 AM

$BNTC interesting insider buy here from a director. Benitec Biopharma Inc.: Aaron Cowen (Director, 10% Owner) Buys 1,481,481 Shares @ Avg Price $13.50 – Form 4

1 · Reply

justiceforb_85 Nov. 6 at 6:37 PM

$BNTC adding on this dip. Hopefully this company can avoid further offerings...

2 · Reply

tymerz Nov. 6 at 2:50 PM

$TERN next up after $BNTC today. BNTC $100M offering, TERN ready to unleash $300M $SPY

0 · Reply

OnTargetCapital Nov. 6 at 2:26 PM

$BNTC They needed to grab some money to pay for EOY bonuses. LOL

0 · Reply

DARKP00L Nov. 6 at 2:12 PM

$BNTC 09:02 on Nov. 06 2025 Benitec Biopharma shares are trading lower after the company announced the pricing of its $100 million offering. #tradeideas

0 · Reply

OpenOutcrier Nov. 6 at 2:06 PM

$BNTC (-14.4% pre) Benitec Biopharma prices $100 million stock offering at $13.50 per share https://ooc.bz/l/83526

0 · Reply

DonCorleone77 Nov. 6 at 11:39 AM

$BNTC Benitec Biopharma $100M share Spot Secondary priced at $13.50

0 · Reply

AStrokeOfLuck Nov. 6 at 6:02 AM

$BNTC

0 · Reply

justiceforb_85 Nov. 5 at 4:17 AM

$BNTC excellent data update for BB-301. FDA fast track designation is outstanding for a disease with no treatment and this is the only company (from my understanding) working on therapy.

0 · Reply

DARKP00L Nov. 4 at 5:47 PM

$BNTC 12:30 on Nov. 04 2025 HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35 #tradeideas

0 · Reply

JarvisFlow Nov. 4 at 5:31 PM

HC Wainwright & Co. has updated their rating for Benitec Biopharma ( $BNTC ) to Buy with a price target of 35.

0 · Reply

JarvisFlow Nov. 4 at 12:33 PM

Citizens has updated their rating for Benitec Biopharma ( $BNTC ) to Market Outperform with a price target of 22.

0 · Reply

Trader_Tom Nov. 3 at 5:31 PM

$BNTC Add PHIO to that statement as well. Down over $2.X from the earlier high.

0 · Reply

bowlerhatsftw Nov. 3 at 5:15 PM

$BNTC i would say thats a pretty uncommon PA

0 · Reply

Peter1735 Nov. 3 at 4:11 PM

$BNTC why is this POS down even lower than the closing price with good news?

0 · Reply

_www_larval_com_ Nov. 3 at 3:23 PM

$BNTC has slipped -8% lower to -10% (~206Kv) in the last few minutes, 11/21 options, follow for more volatility.

0 · Reply

IamactuallyObama Nov. 3 at 1:49 PM

$BNTC WTF happened here. Bought in at 17 unable to sell at 20 now it's 14. Why???

0 · Reply

Trader_Tom Nov. 3 at 12:59 PM

$BNTC There's your typical bio type of move. 15s to 25s to 12s.

0 · Reply

DekmarTrades Nov. 3 at 12:12 PM

$BNTC Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

0 · Reply

justiceforb_85 Oct. 27 at 7:43 PM

$BNTC adding. Look forward to upcoming update on BB-301. High institutional ownership and will have a MOAT with OPMD.

0 · Reply

Market Cap	355.16M
Revenue (ttm)	0.00
Net Income (ttm)	-37.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	228,000
Avg Vol	151,452
Day's Range	N/A - N/A
Shares Out	26.25M
Stochastic %K	46%
Beta	0.23
Analysts	Strong Sell
Price Target	$25.86